vs
Proto Labs Inc（PRLB）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
Tarsus Pharmaceuticals, Inc.的季度营收约是Proto Labs Inc的1.1倍（$151.7M vs $139.3M），Proto Labs Inc净利率更高（5.8% vs -5.5%，领先11.3%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 10.4%），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 5.3%）
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
PRLB vs TARS — 直观对比
营收规模更大
TARS
是对方的1.1倍
$139.3M
营收增速更快
TARS
高出118.0%
10.4%
净利率更高
PRLB
高出11.3%
-5.5%
两年增速更快
TARS
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.3M | $151.7M |
| 净利润 | $8.1M | $-8.4M |
| 毛利率 | 45.6% | — |
| 营业利润率 | 7.1% | -5.3% |
| 净利率 | 5.8% | -5.5% |
| 营收同比 | 10.4% | 128.4% |
| 净利润同比 | 125.4% | 63.8% |
| 每股收益（稀释后） | $0.29 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRLBTARS
| Q1 26 | $139.3M | — | ||
| Q4 25 | $136.5M | $151.7M | ||
| Q3 25 | $135.4M | $118.7M | ||
| Q2 25 | $135.1M | $102.7M | ||
| Q1 25 | $126.2M | $78.3M | ||
| Q4 24 | $121.8M | $66.4M | ||
| Q3 24 | $125.6M | $48.1M | ||
| Q2 24 | $125.6M | $40.8M |
净利润PRLBTARS
| Q1 26 | $8.1M | — | ||
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $7.2M | $-12.6M | ||
| Q2 25 | $4.4M | $-20.3M | ||
| Q1 25 | $3.6M | $-25.1M | ||
| Q4 24 | — | $-23.1M | ||
| Q3 24 | $7.2M | $-23.4M | ||
| Q2 24 | $4.5M | $-33.3M |
毛利率PRLBTARS
| Q1 26 | 45.6% | — | ||
| Q4 25 | 44.2% | — | ||
| Q3 25 | 45.3% | — | ||
| Q2 25 | 44.3% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 42.7% | — | ||
| Q3 24 | 45.6% | — | ||
| Q2 24 | 45.0% | — |
营业利润率PRLBTARS
| Q1 26 | 7.1% | — | ||
| Q4 25 | 5.0% | -5.3% | ||
| Q3 25 | 6.5% | -12.2% | ||
| Q2 25 | 3.7% | -21.6% | ||
| Q1 25 | 3.6% | -33.5% | ||
| Q4 24 | -1.2% | -36.8% | ||
| Q3 24 | 6.8% | -52.3% | ||
| Q2 24 | 4.8% | -81.6% |
净利率PRLBTARS
| Q1 26 | 5.8% | — | ||
| Q4 25 | — | -5.5% | ||
| Q3 25 | 5.3% | -10.6% | ||
| Q2 25 | 3.3% | -19.8% | ||
| Q1 25 | 2.9% | -32.1% | ||
| Q4 24 | — | -34.8% | ||
| Q3 24 | 5.7% | -48.7% | ||
| Q2 24 | 3.6% | -81.6% |
每股收益（稀释后）PRLBTARS
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.25 | $-0.17 | ||
| Q3 25 | $0.30 | $-0.30 | ||
| Q2 25 | $0.18 | $-0.48 | ||
| Q1 25 | $0.15 | $-0.64 | ||
| Q4 24 | $-0.01 | $-0.57 | ||
| Q3 24 | $0.29 | $-0.61 | ||
| Q2 24 | $0.18 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $124.0M | $417.3M |
| 总债务越低越好 | — | $72.4M |
| 股东权益账面价值 | $683.1M | $343.4M |
| 总资产 | $778.6M | $562.2M |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资PRLBTARS
| Q1 26 | $124.0M | — | ||
| Q4 25 | $128.1M | $417.3M | ||
| Q3 25 | $119.2M | $401.8M | ||
| Q2 25 | $103.2M | $381.1M | ||
| Q1 25 | $96.8M | $407.9M | ||
| Q4 24 | $103.1M | $291.4M | ||
| Q3 24 | $100.5M | $317.0M | ||
| Q2 24 | $112.9M | $323.6M |
总债务PRLBTARS
| Q1 26 | — | — | ||
| Q4 25 | — | $72.4M | ||
| Q3 25 | — | $72.3M | ||
| Q2 25 | — | $72.1M | ||
| Q1 25 | — | $72.0M | ||
| Q4 24 | — | $71.8M | ||
| Q3 24 | — | $71.7M | ||
| Q2 24 | — | $71.6M |
股东权益PRLBTARS
| Q1 26 | $683.1M | — | ||
| Q4 25 | $673.9M | $343.4M | ||
| Q3 25 | $664.7M | $335.1M | ||
| Q2 25 | $664.7M | $332.6M | ||
| Q1 25 | $656.8M | $342.5M | ||
| Q4 24 | $670.2M | $224.5M | ||
| Q3 24 | $680.0M | $237.5M | ||
| Q2 24 | $685.2M | $252.2M |
总资产PRLBTARS
| Q1 26 | $778.6M | — | ||
| Q4 25 | $763.4M | $562.2M | ||
| Q3 25 | $756.9M | $534.6M | ||
| Q2 25 | $743.3M | $495.0M | ||
| Q1 25 | $737.5M | $500.8M | ||
| Q4 24 | $743.5M | $377.0M | ||
| Q3 24 | $753.8M | $376.3M | ||
| Q2 24 | $758.2M | $376.8M |
负债/权益比PRLBTARS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.5M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | — | $13.0M |
| 自由现金流率自由现金流/营收 | — | 8.6% |
| 资本支出强度资本支出/营收 | — | 4.2% |
| 现金转化率经营现金流/净利润 | 2.16× | — |
| 过去12个月自由现金流最近4个季度 | — | $-22.3M |
8季度趋势，按日历期对齐
经营现金流PRLBTARS
| Q1 26 | $17.5M | — | ||
| Q4 25 | $16.5M | $19.3M | ||
| Q3 25 | $29.1M | $18.3M | ||
| Q2 25 | $10.6M | $-29.4M | ||
| Q1 25 | $18.4M | $-20.7M | ||
| Q4 24 | $17.3M | $-22.2M | ||
| Q3 24 | $24.8M | $-8.7M | ||
| Q2 24 | $14.4M | $-14.4M |
自由现金流PRLBTARS
| Q1 26 | — | — | ||
| Q4 25 | $8.4M | $13.0M | ||
| Q3 25 | $25.0M | $16.3M | ||
| Q2 25 | $9.1M | $-30.4M | ||
| Q1 25 | $17.1M | $-21.2M | ||
| Q4 24 | $16.5M | $-22.3M | ||
| Q3 24 | $23.2M | $-8.9M | ||
| Q2 24 | $10.2M | $-15.4M |
自由现金流率PRLBTARS
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 8.6% | ||
| Q3 25 | 18.5% | 13.8% | ||
| Q2 25 | 6.7% | -29.6% | ||
| Q1 25 | 13.6% | -27.1% | ||
| Q4 24 | 13.5% | -33.5% | ||
| Q3 24 | 18.5% | -18.6% | ||
| Q2 24 | 8.2% | -37.8% |
资本支出强度PRLBTARS
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 4.2% | ||
| Q3 25 | 3.0% | 1.6% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 1.0% | 0.8% | ||
| Q4 24 | 0.7% | 0.1% | ||
| Q3 24 | 1.2% | 0.6% | ||
| Q2 24 | 3.3% | 2.5% |
现金转化率PRLBTARS
| Q1 26 | 2.16× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.03× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 5.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.44× | — | ||
| Q2 24 | 3.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
TARS
暂无分部数据
